IP Library Granted Patent US 11,660,028
Granted Patent B2
US 11,660,028 · App. 17/303,511 · Granted May 30, 2023

Multispot monitoring for use in optical coherence tomography

Inventors: Walter J. Shakespeare (Macungie, PA); William Henry Bennett (San Jose, CA); Jason T. Iceman (Cheshire, CT); Howard P. Apple (Winter Park, FL); Phillip William Wallace (Bernardsville, NJ); Matthew J. Schurman (Richboro, PA)
Assignee: Masimo Corporation
A61B5/14551A61B5/0066A61B5/0073A61B5/026A61B5/0261A61B5/1455A61B5/14532A61B5/14546A61B5/4875A61B5/725A61B5/7221A61B5/7278A61B2576/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,660,028
App. No.
17/303,511
Granted
May 30, 2023
Kind
B2
Abstract

Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.

Claims (23)

1. A system for determining an analyte level in tissue, the system comprising:

an optical coherence tomography system configured to be aligned to a tissue region of a subject through an optical coupler, wherein the tissue region includes at least a first tissue site and a second tissue site;

a scanner in communication with the optical coherence tomography system and configured to:

scan a beam over the first tissue site using the optical coupler to collect a first set of optical coherence tomography measurements; and

scan the beam over the second tissue site using the optical coupler to collect a second set of optical coherence tomography measurements; and

a processor configured to:

determine, based on the first set of optical coherence tomography measurements, that the first tissue site is an analyte correlating region, wherein an analyte correlating region comprises a tissue site that is valid for measuring an analyte level;

determine, based on the second set of optical coherence tomography measurements, that the second tissue site is not an analyte correlating region and not valid for measuring an analyte level;

cause the scanner to monitor the first tissue site and process optical coherence tomography measurements associated with the first tissue site to measure the analyte level; and

cause the scanner to not monitor and not processing optical coherence tomography measurements associated with the second tissue site.

2. The system of claim 1 , wherein the first and second tissue sites comprise spatially distinct two-dimensional regions of a skin surface of the subject.

3. The system of claim 1 , wherein the scanner is further configured to:

scan the beam over at least one additional tissue site using the optical coupler to collect optical coherence tomography measurements corresponding with each additional tissue site.

4. The system of claim 1 , wherein determining that the first tissue site is valid for measuring an analyte level comprises:

determining a tissue hydration level of the first tissue site.

5. The system of claim 1 , wherein the processor is further configured to:

aggregate a plurality of measures of the analyte level to provide an aggregated measure of the analyte level.

6. The system of claim 5 , wherein the processor is further configured to:

calibrate the optical coherence tomography system using the aggregated measure of the analyte level in the tissue.

7. The system of claim 1 , wherein the tissue region comprises a spatial area of skin of the subject.

8. The system of claim 1 , wherein the analyte level comprises a blood glucose level.

9. The system of claim 1 , wherein at least one of scanning the beam over the first tissue site or scanning the beam over the second tissue site comprises scanning a plurality of tissue depths.

10. The system of claim 1 , wherein areas associated with the first tissue site and the at least second tissue site do not overlap.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2022
From: SHAKESPEARE, WALTER J.; BENNETT, WILLIAM HENRY; ICEMAN, JASON T.; APPLE, HOWARD P.; WALLACE, PHILLIP WILLIAM; SCHURMAN, MATTHEW J.
To: GLUCOLIGHT CORPORATION
Reel/Frame 061189/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2022
From: GLT ACQUISITION CORPORATION
To: MASIMO CORPORATION
Reel/Frame 061189/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2022
From: GLUCOLIGHT CORPORATION
To: GLT ACQUISITION CORP.
Reel/Frame 061189/0070 →
Continuity (6)
Continuation 15799689 · Oct 31, 2017
Continuation 14280294 · May 16, 2014
Continuation 12397577 · Mar 4, 2009
Provisional Application 61068058 · Mar 4, 2008
Provisional Application 61033584 · Mar 4, 2008
Related Publication 20210282679A1 · Sep 16, 2021
Cited By (1)
US 12,329,548